Boothbay Fund Management’s NovoCure NVCR Stock Holding History

Boothbay Fund Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-142,700	Closed	-$8.58M	–	2137
2023 Q1	$8.58M	Buy	142,700 +35,800	+33%	+$2.86M	0.18%	103
2022 Q4	$7.84M	Buy	+106,900	New	+$8.04M	0.18%	97
2021 Q4	–	Sell	-27,000	Closed	-$3.14M	–	2113
2021 Q3	$3.14M	Buy	+27,000	New	+$4.08M	0.09%	282

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Boothbay Fund Management's NVCR Position: Q1 2026 in Review

Boothbay Fund Management increased its NovoCure (NVCR) stake by 63% in Q1 2026, buying an estimated $398K and bringing the position to 82,412 shares worth $898K. The position accounts for 0.01% of the portfolio, ranked #1004.

Boothbay Fund Management first reported a position in NVCR in Q1 2023 and has held it in 3 quarters since. The position peaked at $2.14M in Q1 2023. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Boothbay Fund Management held 82,412 shares of NovoCure worth $898K as of Q1 2026.
Boothbay Fund Management bought 31,870 NovoCure shares in Q1 2026, an estimated $398K.
NovoCure made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1004 holding.
Boothbay Fund Management first reported a position in NovoCure in Q1 2023 and has held it in 3 quarters since.
Boothbay Fund Management's NovoCure position peaked at $2.14M in Q1 2023.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.